Pharmacotherapy of critical asthma syndrome: current and emerging therapies

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


The critical asthma syndrome (CAS) encompasses the most severe, persistent, refractory asthma patients for the clinician to manage. Personalized pharmacotherapy is necessary to prevent the next acute severe asthma exacerbation, not just the control of symptoms. The 2007 National Asthma Education and Prevention Program Expert Panel 3 provides guidelines for the treatment of uncontrolled asthma. The patient's response to recommended pharmacotherapy is highly variable which risks poor asthma control leading to frequent exacerbations that can deteriorate into CAS. Controlling asthma symptoms and preventing acute exacerbations may be two separate clinical activities with their own unique demands. Clinicians must be prepared to use the entire spectrum of asthma medications available but must concurrently be aware of potential drug toxicities some of which can paradoxically worsen asthma control. Medications normally prescribed for COPD can potentially be useful in the CAS patient, particularly those with asthma-COPD overlap syndrome. Immunomodulation with drugs like omalizumab in IgE-mediated asthma syndromes is one important approach. New and emerging drugs address unique aspects of airway inflammation and biology but at a significant financial cost. The pharmacology and toxicities of the agents that may be used in the treatment of CAS to control asthma symptoms and prevent severe exacerbations are reviewed.

Original languageEnglish (US)
Pages (from-to)7-30
Number of pages24
JournalClinical reviews in allergy & immunology
Issue number1
StatePublished - Feb 1 2015

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Pharmacotherapy of critical asthma syndrome: current and emerging therapies'. Together they form a unique fingerprint.

Cite this